EA202192767A1 - Способ лечения опосредуемой нонсенс-мутацией мышечной дистрофии дюшенна у педиатрических пациентов - Google Patents

Способ лечения опосредуемой нонсенс-мутацией мышечной дистрофии дюшенна у педиатрических пациентов

Info

Publication number
EA202192767A1
EA202192767A1 EA202192767A EA202192767A EA202192767A1 EA 202192767 A1 EA202192767 A1 EA 202192767A1 EA 202192767 A EA202192767 A EA 202192767A EA 202192767 A EA202192767 A EA 202192767A EA 202192767 A1 EA202192767 A1 EA 202192767A1
Authority
EA
Eurasian Patent Office
Prior art keywords
muscular dystrophy
mediated
treatment
nonsense mutation
pediatric patients
Prior art date
Application number
EA202192767A
Other languages
English (en)
Russian (ru)
Inventor
Роналд Кун
Джозеф Уильям Макинтош
Original Assignee
ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПиТиСи ТЕРАПЬЮТИКС, ИНК. filed Critical ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Publication of EA202192767A1 publication Critical patent/EA202192767A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EA202192767A 2019-04-10 2020-04-09 Способ лечения опосредуемой нонсенс-мутацией мышечной дистрофии дюшенна у педиатрических пациентов EA202192767A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962831931P 2019-04-10 2019-04-10
PCT/US2020/027382 WO2020210432A1 (en) 2019-04-10 2020-04-09 Method for treating nonsense mutation mediated duchenne muscular dystrophy in pediatric patients

Publications (1)

Publication Number Publication Date
EA202192767A1 true EA202192767A1 (ru) 2021-12-29

Family

ID=72751530

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192767A EA202192767A1 (ru) 2019-04-10 2020-04-09 Способ лечения опосредуемой нонсенс-мутацией мышечной дистрофии дюшенна у педиатрических пациентов

Country Status (10)

Country Link
US (1) US12458629B2 (cg-RX-API-DMAC7.html)
EP (2) EP4473971A3 (cg-RX-API-DMAC7.html)
JP (2) JP2022526643A (cg-RX-API-DMAC7.html)
KR (1) KR20210151131A (cg-RX-API-DMAC7.html)
CN (1) CN114007608A (cg-RX-API-DMAC7.html)
CA (1) CA3135641A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192767A1 (cg-RX-API-DMAC7.html)
IL (1) IL287053A (cg-RX-API-DMAC7.html)
MX (1) MX2021012428A (cg-RX-API-DMAC7.html)
WO (1) WO2020210432A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102665711B1 (ko) * 2021-12-21 2024-05-14 재단법인 아산사회복지재단 Ras 활성도를 이용한 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 Ras 활성 억제제를 포함하는 신경섬유종증 예방 또는 치료용 약학적 조성물
WO2025110781A1 (ko) * 2023-11-24 2025-05-30 재단법인 아산사회복지재단 Ampd3를 포함하는 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 ampd3 저해제를 포함하는 신경섬유종증 예방 또는 치료용 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4101846B1 (en) 2003-04-11 2023-08-02 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
AU2006235115C1 (en) 2005-04-08 2013-02-28 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
DE102005061832A1 (de) 2005-12-23 2007-06-28 Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH Hochdruckentladungslampe mit verbesserter Zündfähigkeit sowie Hochspannungspulsgenerator
EP2387995A1 (en) 2006-03-30 2011-11-23 PTC Therapeutics, Inc. Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
NZ598012A (en) 2006-09-08 2013-08-30 Ptc Therapeutics Inc Processes for the preparation of 1,2,4-oxadiazole benzoic acids
US8101641B2 (en) 2006-09-25 2012-01-24 Ptc Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof
UA99600C2 (en) 2006-09-25 2012-09-10 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
KR20170100072A (ko) 2006-10-12 2017-09-01 피티씨 테라퓨틱스, 인크. 넌센스 돌연변이 억제 치료를 위한 경구 활성 1,2,4-옥사디아졸의 투여 방법
NZ584793A (en) * 2007-10-26 2012-05-25 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
WO2015035091A1 (en) * 2013-09-04 2015-03-12 Cold Spring Harbor Laboratory Reducing nonsense-mediated mrna decay
WO2015134711A1 (en) * 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
CN109152810A (zh) * 2016-01-06 2019-01-04 康德生物医疗技术公司 用于预防和治疗杜氏肌肉萎缩症的方法和组合物

Also Published As

Publication number Publication date
CA3135641A1 (en) 2020-10-15
EP4473971A3 (en) 2025-02-19
EP4473971A2 (en) 2024-12-11
US20220175739A1 (en) 2022-06-09
IL287053A (en) 2021-12-01
WO2020210432A1 (en) 2020-10-15
CN114007608A (zh) 2022-02-01
US12458629B2 (en) 2025-11-04
JP2022526643A (ja) 2022-05-25
EP3952867A1 (en) 2022-02-16
JP2025160227A (ja) 2025-10-22
MX2021012428A (es) 2022-01-19
KR20210151131A (ko) 2021-12-13
WO2020210432A8 (en) 2021-10-28
EP3952867A4 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
CL2019001433A1 (es) Moduladores de la proteína core de la hepatitis b. (divisional solicitud 201800684)
CY1121041T1 (el) Μεθοδοι αγωγης παιδιατρικων ασθενων με τη χρηση δεξμεδετομιδινης
EA202192815A1 (ru) Опосредуемая aav-вектором делеция крупной мутационной "горячей точки" для лечения мышечной дистрофии дюшенна
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MX376691B (es) Composición farmaceutica que comprende un antagonista de il-4r para tratar una infección cutánea.
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
EA201691847A1 (ru) Способы снижения сердечно-сосудистого риска
EP4623976A3 (en) Respiratory mask with nasogastric tube path
EA201800499A1 (ru) Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
EA201890182A1 (ru) Терапевтическое средство для лечения синдрома гунтера и способ его лечения
MX2020013880A (es) Composición que comprende el oligonucleótido antisentido y su uso para el tratamiento de la distrofia muscular de duchenne.
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
BR112022007721A2 (pt) Método para o tratamento da demência
TW201613583A (en) Laquinimod for the treatment of relapsing- remitting multiple sclerosis (RRMS) patients with a high disability status
IL285841A (en) Compositions and methods for treating oculopharyngeal muscular dystrophy (opmd)
MY196979A (en) Method of treating disease by auricular anesthesia of cranial nerves
EA201592058A1 (ru) Применение ландиолола гидрохлорида в длительном лечении тахиаритмии
TN2014000132A1 (en) Dosage regimen for an s1p receptor modulator or agonist
MX2021012428A (es) Metodo para el tratamiento de distrofia muscular de duchenne mediada por mutacion sin sentido en pacientes pediatricos.
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MX344112B (es) Metodo y dispositivo para el tratamiento de trastornos del colesterol en la sangre.
MY203365A (en) Montelukast for the treatment of erosive hand osteoarthritis
MX369090B (es) Sultiame para el tratamiento de apnea del sueño.
WO2019244014A3 (en) New use of inhibitors of monoamine oxidase type b